Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Applying Non-invasive Brain Stimulation in Alzheimer's Rehabilitation (StimoLaMente)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04866979
Recruitment Status : Recruiting
First Posted : April 30, 2021
Last Update Posted : April 30, 2021
Sponsor:
Information provided by (Responsible Party):
Università degli Studi di Trento

Brief Summary:

Presently, few studies have evaluated the clinical impact of rTMS in Alzheimer's disease. Though some studies have demonstrated an improvement, there have been conflicting results, as others do not seem to demonstrate beneficial effects. Furthermore, it is the combined application of rTMS with cognitive training that could represent a real turning point in interventions aiming to slow down cognitive decline resulting from AD. Research has shown that the best way to promote the strengthening of a network is to stimulate the area while simultaneously activating the network (i.e. through cognitive training) which supports the specific function of interest.

Recently, there have been new protocols from animal model research showing that "bursts" of repetitive stimulation at a high theta frequency induce synaptic plasticity in a much shorter time period than required by standard rTMS protocols. This type of rTMS stimulation, theta-burst stimulation (TBS), is therefore even more compelling as a therapeutic intervention given that it includes the benefits previously ascribed to other rTMS protocols, but requires less administration time. Furthermore, studies conducted using both types of stimulation suggest that TBS protocols are capable of producing long term effects on cortical excitability that exceed the efficacy of those using standard rTMS protocols.

This project offers patients the possibility of accessing an innovative non-invasive, and non-pharmacological treatment. The goal is to evaluate the clinical efficacy TBS in patients diagnosed with mild cognitive decline (MCI) and AD, verifying if TBS in conjunction with cognitive training produces results better than those obtainable with only one of the two methodologies alone. Patients will be evaluated throughout the full scope of the treatment period, through clinical assessments and neuropsychological evaluations. We will examine neuroplastic changes by investigating the neural correlates underlying improvements using the multimodal imaging technique: TMS-EEG co-registration. A secondary objective will be to define the most effective stimulation protocol, verifying if TBS applied continuously (cTBS) or intermittently (iTBS) produces better behavioral outcomes. The results will be crucial to gain a better understanding of the mechanisms through which brain stimulation contributes to the promotion of neuroplasticity, and the efficacy of TBS combined with cognitive training.


Condition or disease Intervention/treatment Phase
Alzheimer Disease Mild Cognitive Impairment Device: Experimental: Continuous TBS (cTBS) Device: Intermittent TBS (iTBS) Behavioral: Cognitive training (CT). Device: Sham Stimulation (shamTBS) Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Intervention Model Description:

200 total patients:100 AD patients,100 MCI patients. Random assignment to 1 of 5 protocols (20 AD patients and 20 MCI patients per protocol). Patients will be balanced using MMSE and age matching to create homogeneous groups.

Protocols:

  1. Combination of continuous TBS plus cognitive training (cTBS + CT);
  2. Combination of intermittent TBS plus cognitive training (iTBS + CT);
  3. Continuous TBS only (cTBS);
  4. intermittent TBS only (iTBS);
  5. Cognitive training only (with placebo TBS) (CT). 2 main treatment phases; 1) intensive phase (2 weeks, applied daily 5 times a week, 10 sessions); 2) maintenance phase, (5 weeks, 2 times a week, 10 sessions).

Patients will undergo a clinical, neuropsychological, and neurophysiological evaluation before the start of treatment (baseline, t0=Week1), at the end of the intensive phase (t1= Week 4), at the end of the maintenance phase (t2 = Week 8), and after 3 (t3 = Week 12) and 5 months (t4 = Week 20) from the start of treatment.

Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description: We will implement a randomized, non-pharmacological study, with a double-blind certified medical device (neither the patient nor the clinician / researcher who will carry out the evaluations will be aware of the group to which the patient has been assigned).
Primary Purpose: Treatment
Official Title: StimoLaMente - La Stimolazione Cerebrale Non Invasiva Applicata Alla Riabilitazione Della Malattia di Alzheimer/ StimoLaMente - Applying Non-invasive Brain Stimulation in Alzheimer's Rehabilitation
Actual Study Start Date : April 6, 2021
Estimated Primary Completion Date : January 31, 2023
Estimated Study Completion Date : January 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rehabilitation

Arm Intervention/treatment
Experimental: Combination of continuous TBS plus cognitive training (cTBS + CT)
Continuous mode of TBS applied in conjunction with cognitive training that will commence directly after the stimulation protocol has been completed.
Device: Experimental: Continuous TBS (cTBS)
Application of cTBS. cTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), with a stimulation intensity equal to 80% of the motor threshold value at rest.

Behavioral: Cognitive training (CT).
Cognitive training (memory rehabilitation via RehaCom computer software) of 25 min. The training will be focused on memory rehabilitation, implementing a face-name association paradigm. The software uses an individualized adaptive methodology based on the participant's performance.

Experimental: Combination of intermittent TBS plus cognitive training (iTBS + CT)
Intermittent mode of TBS applied in conjunction with cognitive training that will commence directly after the stimulation protocol has been completed.
Device: Intermittent TBS (iTBS)
Application of iTBS. iTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), alternating 2 seconds of stimulation with a pause of 8 seconds, with a stimulation intensity equal to 80% of the motor threshold value at rest.

Behavioral: Cognitive training (CT).
Cognitive training (memory rehabilitation via RehaCom computer software) of 25 min. The training will be focused on memory rehabilitation, implementing a face-name association paradigm. The software uses an individualized adaptive methodology based on the participant's performance.

Experimental: Continuous TBS only (cTBS)
TBS in continuous mode application, only (without cognitive training).
Device: Experimental: Continuous TBS (cTBS)
Application of cTBS. cTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), with a stimulation intensity equal to 80% of the motor threshold value at rest.

Experimental: Intermittent TBS only (iTBS)
TBS in intermittent mode application, only (without cognitive training).
Device: Intermittent TBS (iTBS)
Application of iTBS. iTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), alternating 2 seconds of stimulation with a pause of 8 seconds, with a stimulation intensity equal to 80% of the motor threshold value at rest.

Active Comparator: Cognitive training only (with sham TBS) (CT).
TBS Sham will be implemented using the same set-up as a true TBS protocol but with "sham stimulation". Directly following sham stimulation (as in the true combination of stimulation + cognitive training protocols), patients will undergo 25 minutes of cognitive training.
Behavioral: Cognitive training (CT).
Cognitive training (memory rehabilitation via RehaCom computer software) of 25 min. The training will be focused on memory rehabilitation, implementing a face-name association paradigm. The software uses an individualized adaptive methodology based on the participant's performance.

Device: Sham Stimulation (shamTBS)
Sham rTMS (TBS) will be administered by applying a 30mm thick piece of wood or plastic to a real TMS coil during "stimulation", and this additional element will be constructed in such a way that it appears to be an integral part of the apparatus such that the patient remains unaware that they are not receiving stimulation (Rossi et al., 2007 ).This 30mm distance is adequate to ensure that the magnetic pulse does not reach the cortex.




Primary Outcome Measures :
  1. Face-name associative memory performance - Measure of Memory Recall [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean change in performance in ability to correctly memorize face/name paired associations [score range min=7, max=n/a, higher score=better outcome]. Patients will start at level 7, the level at which the training software begins paired face/name associations. The software will not allow the patient to go below level 7, so this is the minimum score (level) threshold for all patients.

  2. Mini-Mental State Evaluation (MMSE) Score - Non-Trained Measure of Global Function [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Neuropsychological evaluation using mean changes in the Mini-Mental State Evaluation(MMSE) score Score range is from 0-30, with a score of 25 or higher is classed as "normal". If the score is below 25, the result indicates a possible cognitive impairment. A lower score = worse outcome


Secondary Outcome Measures :
  1. TMS evoked potentials - TEP: Analysis of cortical excitability and inhibition changes induced in the state of excitability/inhibition of brain circuits following the TMS impulse. [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    120 pulses will be delivered to the target area (right DLPFC or left DLPFC) at 110% resting motor threshold intensity during EEG registration. This outcome will analyze cortical excitability and inhibition changes induced in the state of excitability/inhibition of brain circuits following the TMS impulse. The amplitude will be used as a marker of cortical excitability.

  2. Connectivity Index - Connectivity evoked by TMS: cortico-cortical connectivity analysis [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    120 pulses will be delivered to the target area (right DLPFC or left DLPFC) at 110% resting motor threshold intensity during EEG registration. This outcome will analyze changes in the latencies and topographical distribution of the TEPs thus providing a connectivity index. This connectivity index will be used to infer the propagation of the activity from the stimulation site to functionally connected areas.

  3. TMS evoked oscillations: changes induced by TMS and its influence on intrinsic oscillatory activity [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    120 pulses will be delivered to the target area (right DLPFC or left DLPFC) at 110% resting motor threshold intensity during EEG registration. This outcome will analyze changes in responses induced by TMS in the frequency domain for the intrinsic capacity of the stimulated area to generate oscillatory activity in specific frequency bands.

  4. Raven's Colored Progressive Matrices: Evaluation of abstract non-verbal reasoning [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes in test scores [score range 0-36, higher score=better outcome])

  5. Digit Span: Evaluation of short and long term memory (verbal) [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes in test scores [score range 0-9, higher score=better outcome]

  6. Spatial Span: Evaluation of short and long term memory (visuospatial) [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes in test scores [score range 0-10, higher score=better outcome]

  7. Prose Memory:Evaluation of short and long term memory [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes in test scores [score range 0-28, higher score=better outcome];

  8. Free And Cued Selective Reminding Test: Evaluation of short and long term memory [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on tests scores [Immediate: score range 0-36; Deferred: score range 0-12, higher score=better outcome]

  9. Deferred re-enactment of the Complex Figure by Rey Osterrieth: Long term memory evaluation [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on tests scores [score range 0-36, higher score=better outcome]

  10. Token Test: Evaluation of linguistic production [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on tests scores [score range 0-36, higher score = better outcome]

  11. Semantic fluency and Phonemic fluency [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on tests scores: [score range 0-no limits, higher score=better outcome]

  12. Multiple Features Cancellation task: Evaluation of attention and executive function "MFCT" [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes in scores on MFCT Time [score range, min= N/A, max= no limit, higher score=worse outcome; Mean changes in scores on MFCT Accuracy [score range min=0, max=20, higher score=better outcome]; Mean changes in scores on MFCT False alarm [score range min: N/A, max= no limit, high score=worse outcome]

  13. Trail Making test (for A, B and B-A conditions): Evaluation of attention and executive function [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on scores for each condition [score range: min= n/a, max= no limits, higher score=worse outcome]

  14. Stroop test Error and Time: Evaluation of attention and executive function [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on scores [score ranges min=N/A, max= no limit, higher score=worse outcome]

  15. Attentional Matrices: Evaluation of attention and executive function [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on scores [score range 0-60, higher score=better outcome]

  16. Copy of Rey's Complex Figure: Evaluation of practical and visual-constructive skills [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on scores [score range 0-36, higher score=better outcome]

  17. Geriatric Depression Scale, GDS:Evaluation of depressive symptoms in the elderly [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on scores [score range 0-30, higher score=worse outcome]

  18. Questionnaire of Identification of Deficits (QID): Evaluation on quality of life and identification of deficit questionnaire for the patient and caregiver [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on scores [score range 0-52, higher score=worse outcome]

  19. Clinical Insight Rating Scale, (CIRS): Evaluation of awareness of deficits and disease [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on scores [score range 0-8, higher score=worse outcome]

  20. Jefferson Scale: Evaluation of the patient's perception of empathy [ Time Frame: Prior to treatment (baseline=t0=week 1), at the end of the intensive treatment phase (t1=Week 4), at the end of the maintenance phase (t2=Week 8), 3 months post-treatment (t3=Week 12), & 5 months post treatment (t4=Week 20) ]
    Mean changes on scores [score range 0-35, higher score=better outcome]



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

General Inclusion Criteria (must be met for both AD and MCI group):

  • right-handed
  • normal or corrected to normal vision through lenses
  • meet inclusion criteria related to TMS
  • Be able to provide information regarding their cognitive and functional skills, or have a caregiver available who is able to provide the patient information necessary for participation in the study and who is present when signing the patient's informed consent.

AD Patient Inclusion Criteria:

  • Mini Mental State Examination (MMSE) score ≥ 16;
  • Stable intake of cholinesterase inhibitors for at least 3 months before the start of the protocol

MCI Patient Inclusion Criteria:

  • Diagnosis of mild cognitive impairment
  • Mini Mental State Examination (MMSE) score ≥ 24;

Patients will be selected through clinical evaluation (battery of neuropsychological tests at the Neurocognitive Rehabilitation Center (CeRiN) and, in accordance with the APSS, a CSF and PET examination will be performed as well as a further finalized neuropsychological evaluation for research.

Exclusion Criteria:

  • Patients who are unable to perform the tasks required by the experimental procedure;
  • History and / or evidence of any other central nervous system disorder that could be interpreted as a cause of dementia such as structural or developmental abnormality, epilepsy, infectious disease, degenerative or inflammatory/demyelinating diseases of the central nervous system such as Parkinson's disease or Fronto-temporal dementia
  • History of significant psychiatric disease which, in the investigator's judgment, could interfere with study participation
  • History of alcohol or other substance abuse, according to DSM-V criteria, or recent or previous history of drug abuse if this could be a contributing factor to dementia
  • Ongoing treatments with drugs that contain / intake of the following substances: imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel dust), gamma-hydroxybutyrate acid (GHB), theophylline
  • Presence of cardiac pacemakers, electronic prostheses, bio-stimulators, metal inserts or electrodes implanted in the brain or skull or spine.

Absolute exclusion criteria (Criteria for TMS), which in detail are:

  • presence of cardiac pace-makers, artificial heart valves and / or bio-stimulators
  • presence of hearing aids located in the middle ear;
  • presence of metal inserts on the head and shoulders;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04866979


Contacts
Layout table for location contacts
Contact: Carlo Miniussi, PhD 0464 808694 carlo.miniussi@unitn.it

Locations
Layout table for location information
Italy
Centro Interdipartimentale Mente/Cervello - CIMeC Recruiting
Rovereto, Trento, Italy, 38068
Contact: Alessandra Dodich    0464 808162    alessandra.dodich@unitn.it   
Sponsors and Collaborators
Università degli Studi di Trento
Investigators
Layout table for investigator information
Principal Investigator: Carlo Miniussi, PhD Università degli Studi di Trento
  Study Documents (Full-Text)

Documents provided by Università degli Studi di Trento:
Study Protocol  [PDF] March 19, 2020

Publications:
Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmöller J, Carpenter LL, Cincotta M, Chen R, Daskalakis JD, Di Lazzaro V, Fox MD, George MS, Gilbert D, Kimiskidis VK, Koch G, Ilmoniemi RJ, Lefaucheur JP, Leocani L, Lisanby SH, Miniussi C, Padberg F, Pascual-Leone A, Paulus W, Peterchev AV, Quartarone A, Rotenberg A, Rothwell J, Rossini PM, Santarnecchi E, Shafi MM, Siebner HR, Ugawa Y, Wassermann EM, Zangen A, Ziemann U, Hallett M; basis of this article began with a Consensus Statement from the IFCN Workshop on "Present, Future of TMS: Safety, Ethical Guidelines", Siena, October 17-20, 2018, updating through April 2020. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021 Jan;132(1):269-306. doi: 10.1016/j.clinph.2020.10.003. Epub 2020 Oct 24. Review.

Layout table for additonal information
Responsible Party: Università degli Studi di Trento
ClinicalTrials.gov Identifier: NCT04866979    
Other Study ID Numbers: UStudidiTrento
First Posted: April 30, 2021    Key Record Dates
Last Update Posted: April 30, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Individual participant data be available (including data dictionaries) after de-identification.

The data in particular that will be shared are individual participant data that underlie the results reported in the published article, after de-identification (text, tables, figures, and appendices).

Supporting Materials: Study Protocol
Time Frame: The data will be available immediately following article publication, and the time frame for sharing this data will have no foreseen end-date.
Access Criteria:

The data will be shared with Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose, for research purposes only.

The only data will be shared will be those which aid in achieving the research aims of the approved proposal, previously approved by the above mentioned independent ethical review committee.

Proposals for data sharing should be directed to carlo.miniussi@unitn.it following ethical committee approval. To gain access, data requestors will need to sign a data access agreement. The sharing of the data will be contingent on the above-mentioned criteria, namely, the approval of an independent ethics committee and the relevance of the requested data as it pertains to the research question.


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Università degli Studi di Trento:
Transcranial Magnetic Stimulation
Theta Burst Stimulation
Alzheimer Disease
Mild Cognitive Impairment
Memory
TMS-EEG
Electroencephelography
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognitive Dysfunction
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders